Pre-Meeting Categorical Seminars

Additional registration fees may apply. A Categorical seminar is included for Weekend Only Attendees. *Members who are also members of a Council or Center will receive a $20 discount when registering online for a Physician/Scientist Categorical.

SNMMI's Annual Meeting offers full-day categorical seminars to provide you with a deeper level of understanding as you examine a single topic of clinical, scientific, or academic interest. 

(CAT1) Radioiodine Theragnostics: Continuing the Update of the Controversies of the Management of Differentiated Thyroid Cancer

Sponsored by the Therapy Center of Excellence
Nuclear Medicine performs more I-131 therapies than all other nuclear medicine therapies combined. The ATA (American Thyroid Association) 2015 guidelines has 34 recommendations that affect the practice of nuclear medicine involving the imaging and therapy of thyroid nodules and differentiated thyroid cancer. 

Learning Objectives

  • Discuss the literature for and against 30 vs >100mCi of I-131 for adjuvant treatment (e.g. a major controversial issue with many miss interpretations of the literature)
  • Describe the options for the evaluation and management of patients who have positive thyroglobulin levels and negative radioiodine sans, ultrasound, 18F FDG scans and contrast CT. This is a update from last year
  • List and explain the preventive measure that may be implemented to help reduce the frequency and/or severity of many of side effects of I-131 (e.g. sialoadenitis, ephiphora, nausea/vomiting, and second primary malignancies, to name only a few
  • Explain the problems with the present ATA definitions for radioiodine refractory patients (e.g. important not to exclude a patient from a potential valuable I-131 therapy)
  • List several of the more promising areas of research involving radioiodine theragnostics (egg. 18F tetrafluoroborate, selumetinib, I-124, 3DRD dosimetry, 30 mCi “blind scans,” and several more)


(CAT2) Molecular Imaging of Inflammation and Infection: Focusing on the Future

Sponsored by the General Clinical Nuclear Medicine Council
This comprehensive session is designed for imaging specialists, investigators, technologists, and clinicians who want both a review of the current status of molecular imaging of inflammation and infection, as well as an update on new and emerging developments in the field. This seminar will include reviews of currently available single photon and positron emitting radiopharmaceuticals—including their indications, advantages and disadvantages, and pitfalls in imaging infection and inflammation. The role of molecular imaging in inflammatory arthritis, atherosclerosis & vulnerable plaque, tuberculosis, and musculoskeletal infection will be addressed. This seminar also will cover recent advances in the use of molecular imaging for monitoring treatment response, the development of new radiopharmaceuticals for imaging inflammation and infection, including infection specific agents, and PET/MR. Molecular Imaging of infection and inflammation is a very broad field, with numerous novel and innovative developments in imaging for diagnosis and prognosis. While it is not possible, even with a full day seminar, to cover the entire field, this categorical seminar will cover many important topics not previously addressed.

Learning Objectives

  • Compare available radiopharmaceuticals for specific clinical indications in the assessment of inflammation and infection.
  • Be acquainted with infection specific radiopharmaceuticals.
  • Compare advantages and disadvantages of molecular imaging of infection and inflammation.
  • Describe the role of molecular imaging in inflammatory processes such as arthritis, and atherosclerosis
  • Explain the role of molecular imaging in tuberculosis and musculoskeletal infections.
  • Discuss the role of molecular imaging for monitoring treatment response.
  • Be acquainted with the role of PET/MR in inflammation and infection.


(CAT3) PSMA Radioligand Therapy (PRLT) and Imaging of Prostate Cancer: Current State and Future Perspectives

Sponsored by the Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), ENTS Center of Excellence
In this categorical seminar, participants will assess the current state-of-the-art options for therapy of end stage prostate cancer. This seminar will explore a broad spectrum of the use of PSMA ligands for therapy of prostate cancer, including radiochemical aspects, preclinical studies, the role of PSMA PET/CT (using Ga68 and F-18) clinical utility, and the state-of-the-art role including newer radionuclides and alpha targeted radioligand therapy.

Learning Objectives

  • Discuss the relevance of PSMA molecule
  • Recognize the current therapeutic strategies for end-stage prostate cancer
  • Describe targeting PSMA for theranostics of prostate cancer
  • Explain the role of PSMA PET/CT in selection of patients and follow-up/ therapeutic response assessment
  • Learn about the state-of-the-art clinical utility of PSMA radioligand therapy using beta- and alpha-emitting radionuclides


(CAT4) Radiomics and Machine Learning Methods and Applications in Radiology and Nuclear Medicine

Sponsored by the Computer and Instrumentation Council and the Center for Molecular Imaging Innovation and Translation
In this categorical seminar, participants will receive a general introduction and more in-depth discussion into the emerging fields of radiomics and machine learning as applied to imaging, including an overview of various applications in nuclear medicine. The seminar will provide both a foundational overview for the methodology and significant success of the field of machine learning in general, and how these methods are increasingly applied in imaging including anatomic radiology and nuclear medicine/molecular imaging. Various applications will be discussed, including emphasis on oncological PET imaging. Discussions will also include the field of radiogenomics (imaging genetics), and how combination of radiomic and genomic features hold promise towards derivation of effective biomarkers of disease.

Learning Objectives

  • Gain overall understanding and insight into the field of machine learning as an important subset of the field of artificial intelligence in current non-medical and medical applications
  • Gain overall understanding and insight into the field of deep learning as an important, emerging subset of the field of machine learning
  • Discuss motivations for extraction and assessment of radiomic features including those related to heterogeneity in uptake of radiopharmaceuticals
  • List different categories of radiomic features, and the pitfalls in generation of numerous radiomic features
  • Gain insight into univariate and multivariate methods that compare and combine radiomic features, and pitfalls related to the curse of dimensionality and overfitting.
  • Gain insight into how (and how much) machine learning and/or radiomics have the potential to contribute towards realization of precision medicine


(CAT5) Cased Based Review of Advanced Cardiovascular Imaging

Sponsored by the Cardiovascular Council
This categorical seminar will offer cardiovascular imaging specialists and clinicians, scientists, technologists, and trainees with a case-based, interactive and multimodality presentation to increase understanding of advanced multimodality cardiovascular imaging as applied to coronary artery disease, congestive heart failure and inflammation and infection. Through these case presentations, participants will gain a better understanding of advanced multimodality cardiovascular imaging, and improve their ability to incorporate test results into clinical reports and patient management. In addition, patient outcomes will improve with understanding of the strengths and limitations of imaging and role of imaging in decisions about patient management.

Learning Objectives

  • Optimize test selection for patients with chest pain or known coronary artery disease in terms of functional vs anatomic imaging and PET vs SPECT myocardial perfusion imaging.
  • Appreciate appropriate selection of imaging for patients with ischemic LV dysfunction being considered for revascularization and also patients with congestive heart failure and possible infiltrative cardiomyopathy.
  • Describe the applications of radionuclide imaging for evaluation of arrhythmogenicity, cardiac sarcoidosis, infection of cardiac devices and endocarditis and also large vessel vasculitis and appreciate their potential role in optimizing patient care.


(CAT6) Clinical Relevance of Molecular Neuroimaging

Sponsored by the Brain Imaging Council
The field of molecular neuroimaging has been developing rapidly in the recent years. Numerous novel tracers have been introduced ranging from approved tracers for imaging amyloid-depositions to novel tracers for tau-aggregates or synaptic function. Finally, novel imaging procedures allow to monitor complex system neuropathologies, including inflammation, which may underlie numerous disorders of the central nervous system rather than one particular type of disease. In this categorical seminar, participants will examine how molecular imaging of such processes may be beneficial for research and clinical applications. The seminar will also explore how new options can be potentially applied to solve clinical questions, including the advances in tracer development accompanied by methodological progress in instrumentation such as integrated PET/MR, and new methods for image processing including artificial intelligence approaches.

Learning Objectives

  • Discuss the status and clinical relevance of quantitative amyloid-imaging approaches and the results of large clinical multi-center trials
  • Explain how synaptic imaging may influence clinical routine in neuroscience
  • Describe the potential of integrated PET/MR and novel image analysis procedures such as artificial intelligence
  • Recognize how complex system neuropathologies such as inflammation can be monitored and which clinical benefit may arise from such examinations


(CAT7) PET/CT and PET/MR for Adults and Children: Fundamental and Evolving Practices

Sponsored by the PET Center of Excellence, Pediatric Imaging Council, and Computer and Instrumentation Council
This categorical seminar will provide practitioners—physicians, physicists/ scientists, technologists and resident/ students— with a practical nuts and bolts review of clinical PET/CT and PET/MR. The seminar will feature new technological developments in PET/CT and PET/MR instrumentation and the emerging role of machine learning, choosing and optimizing PET/CT and PET/MR protocols, and explore practical approaches to radiation dose reduction. Advanced concepts will also be addressed, including an approach to PET/CT and PET/MR with newly FDG-approved radiotracers, as well as updates in brain PET, myocardial PET, prostate PET and neuroendocrine PET.

Learning Objectives

  • Review common PET/CT and PET/MR artifacts and clinically important normal variants.
  • Discuss management of incidental findings on PET, CT and MRI.
  • Review bread and butter as well as challenging PET cases in pediatrics and adults.
  • Provide and update on PET in brain, myocardial, neuroendocrine, and prostate disease.
  • Introduce new technological developments in PET/CT and PET/MR instrumentation.
  • Discuss protocoling options to maximize image quality and reduce radiation.


(CAT8) Primer on Radionuclide Dosimetry

Sponsored by the MIRD Committee
This categorical seminar will introduce the recently updated MIRD Committee Primer on Dosimetry. A series of sessions will be presented that correspond to the different primer chapters. Participants will review the MIRD schema for dosimetry including application to both macroscopic organs, cell-level calculations and it’s use in both therapy and diagnosis. Measurements required for dosimetry will be discussed. Dosimetry, forms and rules for investigational human use as well an overview of the various forms required by international, US and institutional regulatory and compliance bodies will be examined.

Learning Objectives

  • Use currently available tools to calculate organ absorbed doses for diagnostic and therapeutic agents
  • Describe radiobiological concepts and how they apply to diagnostic and therapeutic agents
  • List the data required to perform dosimetry calculations
  • Identify those uncertainties that have the greatest practical impact and how to address them (importance of QC/QA)
  • Discuss radiobiology overview for diagnosis and therapy